

## A-Detail™ Fact Sheet (Canada)

# Clobetasone Butyrate 0.05% Cream and Ointment

### Overview

*Clobetasone Butyrate 0.05% Cream and Ointment (marketed by GSK Consumer Healthcare under the name Eumovate®) is a moderate potency corticosteroid used to treat eczema, seborrheic dermatitis and other corticosteroid responsive skin conditions which do not require the use of a more potent topical corticosteroid.*

### Clinical Experience

Hydrocortisone 1% remains a mainstay for treatment of facial eczema and skin folds, but is often not effective for treating eczema affecting other body areas. Eumovate® has been shown to be more effective than hydrocortisone 1.0% for treating atopic eczema, and skin thinning has not been reported with short term use. There was negligible systemic absorption. Eumovate® has recently become available for short term use in adults and children over 10 who have acute eczema and allergic dermatitis at pharmacies in the UK.

### Patient Profiles

Suitable candidates include patients with a steroid responsive rash who don't require superpotent or potent topical corticosteroids. Unsuitable candidates include patients with:

- a known hypersensitivity to the topical corticosteroid or to the vehicle
- mycobacterial, fungal, and/or viral infections
- scabies or pediculosis
- Chronic ulcers
- acne, rosacea and perioral dermatitis or routine gingivitis.

### Dosing

Anatomic area	Amount for b.i.d. application
Face and neck	2.5gm
Anterior/posterior trunk	7gm
Arm	3gm
Hand (both sides)	1gm
Leg	6gm
Foot	2gm

### Efficacy

Clobetasone butyrate 0.05% cream with its moisturizing emollient base is reported to provide better healing properties than hydrocortisone 1% cream. Its high glycerol content promotes skin hydration and protects and moisturizes the skin.

### Side Effects, Risks, Compliance & Monitoring

#### Side effects

Topical corticosteroid molecules can be absorbed percutaneously in significant quantities to cause systemic adverse effects, though the actual number of reports of such effects is small and seems to involve gross misuse of a topical corticosteroid preparation. Local adverse effects occur more often, though they are generally uncommon and include skin atrophy and addiction/rebound syndrome.

#### Risk factors

Risk factors for systemic side effects and local atrophy include young age, liver or renal disease, the amount and potency of topical corticosteroids applied and the use of occlusion. Local atrophy risk factors include young age, potency, the use of occlusion and the location of treatment.

#### Compliance

There are misconceptions about commonly prescribed topical corticosteroids which can result in non-compliance.

#### Monitoring

A follow-up visit and patient education are the most effective methods for ensuring that the patient's benefits are optimized and adverse events are minimized.

### A-Details™ "An Online Academic Drug Presentation Written By Drs. for Drs."

The content is third party, academic-based and includes clinical evidence and practical experience. View the complete A-Detail™ for Eumovate® and other drugs at [www.SkinCareGuide.ca](http://www.SkinCareGuide.ca) or [www.EczemaGuide.ca](http://www.EczemaGuide.ca). Just click on Physician's View and A-Details.